Dong-A Progresses In Diabetes With Lat Am Deal, New Study
This article was originally published in PharmAsia News
With the global diabetes treatment market expected to show continued growth, South Korea's Dong-A ST is making progress in the sector by signing an additional licensing out contract for its new drug and successfully completing a Phase II U.S. study with a potential diabetic neuropathy therapy.
You may also be interested in...
Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.
With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.
Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.